Carlsmed announced today that it raised $52.5 million in a Series C funding round co-led by B Capital and U.S. Venture Partners.
The Carlsbad, California-based AI-enabled personalized surgery company plans to use the funds to accelerate commercialization efforts. It wants to boost the commercialization of its aprevo personalized spine surgery platform for lumbar fusion procedures, in particular.
The company also hopes to put the funds toward developing aprevo for cervical fusions. Carlsmed plans to launch that offering in 2025.
Carlsmed already holds FDA breakthrough device designation for the aprevo lumbar and cervical patient-specific interbody fusion devices. Its implantable devices and software platforms hold FDA clearance for lumbar spine fusion. That includes in anterior, lateral and transforaminal approaches.
Dr. Robert Mittendorff, general partner and head of healthcare at B Capital, said in a news release that Carlsmed is “transform…